Epigenomics

Epigenomics EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Epigenomics (ECX.F) as of Nov 4, 2026 is -9.33. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -1.85 — a change of 404.89% (lower).

EV/OCF

-9.33

YoY

404.89%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Epigenomics is 2024 -9.33 . EV/OCF (Enterprise Value to Operating Cash Flow) of Epigenomics was 2023 -1.85 . It decreases by 404.89% lower compared to the previous year.

The Epigenomics EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2017
0.67 EUR
Jan 1, 2018
1.52 EUR
Jan 1, 2019
0.69 EUR
Jan 1, 2020
0.31 EUR
Jan 1, 2021
5.23 EUR
Jan 1, 2022
-0.53 EUR
Jan 1, 2023
-1.85 EUR
Jan 1, 2024
-9.33 EUR
The Epigenomics EV/OCF history
YEAREV/OCFYoY
-9.33+404.89%
-1.85+249.27%
-0.53-110.11%
5.23+1,573.84%
0.31-54.84%
0.69-54.33%
1.52+125.96%
0.67-17.18%
0.81-2.07%
0.83+26.80%
0.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Epigenomics Stock analysis

What does Epigenomics do? Epigenomics AG develops and commercializes blood-based diagnostic products for cancer screening and diagnosis, primarily targeting colorectal and lung cancer. The company's main products are Epi proColon, a blood test for colorectal cancer screening, and Epi proLung, a blood test for detecting lung cancer in blood plasma. These products are sold to healthcare providers and laboratories in Europe and the United States, where the company operates its commercial activities. The firm also generates revenue from services related to research, product development, regulatory approval, and manufacturing of in-vitro diagnostic (IVD) products. Epigenomics AG's revenue streams are derived from the sale of Epi proColon and Epi proLung to medical institutions and diagnostic laboratories across its operational regions. The company's focus on blood-based diagnostics for cancer screening positions it within the molecular diagnostics sector, with a specific emphasis on non-invasive testing solutions. Its business model relies on the commercialization of proprietary diagnostic tests and associated services to healthcare providers and laboratories. The company's products are designed to support early cancer detection, with Epi proColon targeting colorectal cancer screening and Epi proLung addressing lung cancer detection. These tests are marketed to healthcare professionals and laboratories in Europe and the United States, where Epigenomics AG has established its commercial presence. The firm's service offerings include research, product development, regulatory support, and manufacturing for IVD products, which contribute to its overall revenue. Epigenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Epigenomics stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Epigenomics is -9.33 in 2024.

EV/OCF (Enterprise Value to Operating Cash Flow) of Epigenomics changed from -1.85 to -9.33, representing a 404.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Epigenomics since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Epigenomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Epigenomics

All Key Metrics — Epigenomics